0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BMS21011

Anti-LAG-3 monoclonal antibody

Active
  • Project profile
    Project name: Anti-LAG-3 monoclonal antibody
    Indications: Tumors such as melanoma, non-small cell lung cancer,liver cancer, gastric carcinoma
    Research phase: Cell line screening
    Cooperation demands: Project authorization, transfer or co-development. (project’s company is seeking for external cooperation to accelate drug research and development.)
  • Highlights
    1. This project’s antibody's binding epitope was unique,which can inhibit LAG3 from binding to FGL1 or blocking the binding to MHC II;
    2. This project’s antibody could significantly inhibit tumor growth when used alone or combined with PD-1 antibody. At the same dose, this project’s antibody’s effectiveness was better than MK4280 (used alone or combined with PD-1 antibody);
    3. Currently combination of LAG-3 antibody and PD-1 antibody has showed excellent anti-tumor synergy in clinical trials, therefore LAG-3 antibody has great clinical development prospect and low development risk. Targeting LAG-3 ntibody drugs will play an essential role in anti-tumor drug market in the future;
    4. Clear mechanism, broad indications and huge market potential.
  • Project Introduction

    1. Drug type: Monoclonal antibody;

    2. Mechanism: As one of the immuno-checkpoint targets, LAG-3 has relatively more clinical data and certain drugability. The expression of LAG-3 negatively regulated specific T cells. Inhibiting the function of LAG-3 can enhance the anti-tumor effect of specific CD8+T cells and can also regulate immune response by inhibiting T cells over-activation;

    3. Indications: Tumors such as melanoma, non-small cell lung cancer,liver cancer, gastric carcinoma;

    4. Research phase: Cell line screening;

    5. Research progress: Completed antibody construction, affinity, in vitro and in vivo functional validation and in vivo pharmacodynamics study. Now the project is waiting for staring CMC development.

Comments (0)